Log in

bluebird bio News Headlines (NASDAQ:BLUE)

$47.77
+1.20 (+2.58 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$43.71
Now: $47.77
$48.83
50-Day Range
$40.39
MA: $69.33
$91.57
52-Week Range
$38.95
Now: $47.77
$163.43
Volume1.06 million shs
Average Volume1.08 million shs
Market Capitalization$2.66 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.36

Headlines

bluebird bio (NASDAQ BLUE) News Headlines

Source:
DateHeadline
Five things you need to know today, and why you should question that mapFive things you need to know today, and why you should question that map
www.bizjournals.com - March 27 at 3:14 PM
bluebird bio (NASDAQ:BLUE) Price Target Cut to $107.00 by Analysts at BMO Capital Marketsbluebird bio (NASDAQ:BLUE) Price Target Cut to $107.00 by Analysts at BMO Capital Markets
www.americanbankingnews.com - March 27 at 11:52 AM
bluebird bio (NASDAQ:BLUE) Receives Hold Rating from William Blairbluebird bio (NASDAQ:BLUE) Receives Hold Rating from William Blair
www.americanbankingnews.com - March 27 at 10:02 AM
Stifel likes bluebird bio in premarket analyst actionStifel likes bluebird bio in premarket analyst action
seekingalpha.com - March 27 at 8:23 AM
$9.24 Million in Sales Expected for bluebird bio Inc (NASDAQ:BLUE) This Quarter$9.24 Million in Sales Expected for bluebird bio Inc (NASDAQ:BLUE) This Quarter
www.americanbankingnews.com - March 27 at 1:42 AM
bluebird bio (NASDAQ:BLUE) Stock Rating Upgraded by Stifel Nicolausbluebird bio (NASDAQ:BLUE) Stock Rating Upgraded by Stifel Nicolaus
www.americanbankingnews.com - March 26 at 7:46 PM
bluebird bio (NASDAQ:BLUE) PT Lowered to  at Piper Sandlerbluebird bio (NASDAQ:BLUE) PT Lowered to at Piper Sandler
www.americanbankingnews.com - March 26 at 7:46 PM
bluebird bio (NASDAQ:BLUE) Receives Buy Rating from Wells Fargo & Cobluebird bio (NASDAQ:BLUE) Receives Buy Rating from Wells Fargo & Co
www.americanbankingnews.com - March 26 at 4:11 PM
Biotech delays U.S. gene therapy launch due to outbreak, FDA discordBiotech delays U.S. gene therapy launch due to outbreak, FDA discord
finance.yahoo.com - March 26 at 2:15 PM
bluebird bio Inc (NASDAQ:BLUE) Given Average Recommendation of "Buy" by Brokeragesbluebird bio Inc (NASDAQ:BLUE) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 26 at 1:57 PM
Bluebird bio updates on business and clinical programs amid COVID-19Bluebird bio updates on business and clinical programs amid COVID-19
seekingalpha.com - March 26 at 9:14 AM
BRIEF-Bluebird Bio Provides Assessment Of Impact Of COVID-19BRIEF-Bluebird Bio Provides Assessment Of Impact Of COVID-19
www.reuters.com - March 26 at 9:14 AM
bluebird bio Provides Assessment of Impact of COVID-19, Update on Business Operations and Clinical Program Developmentbluebird bio Provides Assessment of Impact of COVID-19, Update on Business Operations and Clinical Program Development
finance.yahoo.com - March 26 at 9:14 AM
-$3.89 Earnings Per Share Expected for bluebird bio Inc (NASDAQ:BLUE) This Quarter-$3.89 Earnings Per Share Expected for bluebird bio Inc (NASDAQ:BLUE) This Quarter
www.americanbankingnews.com - March 26 at 12:48 AM
CAR-T Cell Therapy Market 2020 Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2026CAR-T Cell Therapy Market 2020 Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2026
www.benzinga.com - March 24 at 9:13 AM
Global Adrenoleukodystrophy (ALD) Market Report 2020, Featuring Emerging Drugs Lenti D (Bluebird Bio) and Leriglitazone (Minoryx Therapeutics)Global Adrenoleukodystrophy (ALD) Market Report 2020, Featuring Emerging Drugs Lenti D (Bluebird Bio) and Leriglitazone (Minoryx Therapeutics)
www.globenewswire.com - March 20 at 8:25 AM
Gene Therapy Market 2020: Worldwide Industry Overview, Supply Demand and Shortage, Trends, Demand, Overview, Forecast 2026Gene Therapy Market 2020: Worldwide Industry Overview, Supply Demand and Shortage, Trends, Demand, Overview, Forecast 2026
www.marketwatch.com - March 19 at 9:02 AM
Bluebird Bio IncBluebird Bio Inc
www.bloomberg.com - March 18 at 1:12 PM
Adrenoleukodystrophy Drugs Market Future Investment and Forecast 2029 | Applied Genetic Technologies Corp and Bluebird Bio IncAdrenoleukodystrophy Drugs Market Future Investment and Forecast 2029 | Applied Genetic Technologies Corp and Bluebird Bio Inc
www.marketwatch.com - March 16 at 7:59 AM
Thalassemia Market 2020 Market by Types and Application, Market Segmentation, Industry Share, Trends, Growth Factor Research Report by 2026Thalassemia Market 2020 Market by Types and Application, Market Segmentation, Industry Share, Trends, Growth Factor Research Report by 2026
www.marketwatch.com - March 13 at 8:38 AM
Is T-Cell Immunotherapy Market Trapped Between Growth Expectations and Uncertainty?Is T-Cell Immunotherapy Market Trapped Between Growth Expectations and Uncertainty?
www.marketwatch.com - March 12 at 2:01 PM
Is bluebird bio a Millionaire-Making Biotech?Is bluebird bio a Millionaire-Making Biotech?
www.fool.com - March 4 at 7:43 AM
Zacks: Brokerages Anticipate bluebird bio Inc (NASDAQ:BLUE) Will Announce Quarterly Sales of $9.24 MillionZacks: Brokerages Anticipate bluebird bio Inc (NASDAQ:BLUE) Will Announce Quarterly Sales of $9.24 Million
www.americanbankingnews.com - March 4 at 2:28 AM
bluebird bio (BLUE) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshowbluebird bio (BLUE) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow
seekingalpha.com - February 20 at 1:32 PM
bluebird bio, Inc. Just Released Its Annual Results And Analysts Are Updating Their Estimatesbluebird bio, Inc. Just Released Its Annual Results And Analysts Are Updating Their Estimates
finance.yahoo.com - February 20 at 8:31 AM
Stock Alert: Bluebird Bio Stock Down 8% On Mixed Q4 ResultsStock Alert: Bluebird Bio Stock Down 8% On Mixed Q4 Results
www.nasdaq.com - February 19 at 1:43 PM
Why bluebird bios Q4 Results Really Dont MatterWhy bluebird bio's Q4 Results Really Don't Matter
www.fool.com - February 19 at 8:43 AM
bluebird bio Beats Its Q4 Revenue Target but Misses on EPSbluebird bio Beats Its Q4 Revenue Target but Misses on EPS
www.nasdaq.com - February 18 at 11:13 PM
bluebird bio EPS misses by $0.25, beats on revenuebluebird bio EPS misses by $0.25, beats on revenue
seekingalpha.com - February 18 at 6:13 PM
BRIEF-Bluebird Bio Reports Qtrly Net Loss Per Share $4.04BRIEF-Bluebird Bio Reports Qtrly Net Loss Per Share $4.04
www.reuters.com - February 18 at 6:13 PM
bluebird bio Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Operational Progressbluebird bio Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Operational Progress
finance.yahoo.com - February 18 at 6:13 PM
Some bluebird bio (NASDAQ:BLUE) Shareholders Are Down 35%Some bluebird bio (NASDAQ:BLUE) Shareholders Are Down 35%
finance.yahoo.com - February 17 at 1:40 PM
Analysts Estimate Bluebird Bio (BLUE) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Bluebird Bio (BLUE) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - February 13 at 1:53 PM
Gene Therapy Market 2020 - 2026, Details in Relation to the Value, Supply Chain Analysis and Recent Technological DevelopmentsGene Therapy Market 2020 - 2026, Details in Relation to the Value, Supply Chain Analysis and Recent Technological Developments
www.marketwatch.com - February 12 at 8:33 AM
Better Buy: bluebird bio vs. Gilead SciencesBetter Buy: bluebird bio vs. Gilead Sciences
www.nasdaq.com - February 12 at 8:33 AM
bluebird bio Announces Upcoming Investor Eventsbluebird bio Announces Upcoming Investor Events
finance.yahoo.com - February 5 at 8:53 AM
Gene Therapy Market Growth 2020| Introduction of New Tools in Gene Therapy to Drive the MarketGene Therapy Market Growth 2020| Introduction of New Tools in Gene Therapy to Drive the Market
www.marketwatch.com - February 3 at 8:53 AM
Bluebird up 2% premarket on two new bullish callsBluebird up 2% premarket on two new bullish calls
seekingalpha.com - February 3 at 8:53 AM
bluebird bio, Inc.bluebird bio, Inc.
247wallst.com - January 30 at 10:35 PM
Cancer Gene Therapy Market 2020 Healthcare Analysis and Clinical Reviews Report – Adaptimmune, Bluebird bio, CelgeneCancer Gene Therapy Market 2020 Healthcare Analysis and Clinical Reviews Report – Adaptimmune, Bluebird bio, Celgene
www.marketwatch.com - January 28 at 8:00 AM
Cancer Gene Therapy Market Size, Share, Analysis, Opportunities and Forecast 2019 - 2025Cancer Gene Therapy Market Size, Share, Analysis, Opportunities and Forecast 2019 - 2025
www.marketwatch.com - January 27 at 7:35 AM
Alpha Thalassemia Treatment Market Analysis by Top Companies | Novartis AG, Celgene Corporation, Bluebird Bio, Acceleron Pharma, Shire PlcAlpha Thalassemia Treatment Market Analysis by Top Companies | Novartis AG, Celgene Corporation, Bluebird Bio, Acceleron Pharma, Shire Plc
www.marketwatch.com - January 27 at 7:35 AM
Gene Therapy Market 2020: Development, Key Opportunity, Industry Analysis, Regional Overview, Forecast to 2026Gene Therapy Market 2020: Development, Key Opportunity, Industry Analysis, Regional Overview, Forecast to 2026
www.marketwatch.com - January 23 at 5:43 PM
First Week of March 20th Options Trading For bluebird bio (BLUE)First Week of March 20th Options Trading For bluebird bio (BLUE)
www.nasdaq.com - January 23 at 5:43 PM
Gene Therapy Market Size, Trends, Analysis, Demand, Outlook and Forecast to 2024Gene Therapy Market Size, Trends, Analysis, Demand, Outlook and Forecast to 2024
www.marketwatch.com - January 20 at 8:42 AM
What s driving Cancer Gene Therapy Market? Stay up-to-date with emerging trends aheadWhat 's driving Cancer Gene Therapy Market? Stay up-to-date with emerging trends ahead
www.marketwatch.com - January 16 at 6:10 PM
Gene therapies test Europe’s willingness to payGene therapies test Europe’s willingness to pay
www.ft.com - January 15 at 11:43 PM
Bluebird Hires New Europe Head as Gene Therapy Rollout StartsBluebird Hires New Europe Head as Gene Therapy Rollout Starts
www.msn.com - January 15 at 1:43 PM
Bluebird bio launches Zynteglo for TDT in GermanyBluebird bio launches Zynteglo for TDT in Germany
seekingalpha.com - January 13 at 5:27 PM
bluebird bio: CAR-T Pioneer Is A Battleground Stock Among Analystsbluebird bio: CAR-T Pioneer Is A Battleground Stock Among Analysts
seekingalpha.com - January 13 at 4:12 AM
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: Bid-Ask Spread

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel